Suppliers and packagers for tpoxx

tpoxx

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627	NDA	SIGA Technologies, Inc.	50072-200-42	42 CAPSULE in 1 BOTTLE (50072-200-42)	2018-08-31
Siga Technologies	TPOXX	tecovirimat	SOLUTION;INTRAVENOUS	214518	NDA	SIGA Technologies, Inc.	50072-010-01	7 VIAL in 1 CARTON (50072-010-01) / 20 mL in 1 VIAL (50072-010-30)	2022-05-31

Suppliers and packagers for tpoxx

Last updated: June 11, 2026

TPOXX (tecovirimat) Suppliers: Who Manufactures, Supplies, and Controls the Patent-Linked Supply Chain

Executive summary: TPOXX (tecovirimat) is manufactured and supplied through a constrained, government-linked supply chain. Commercial availability is limited, and production is dominated by the original developer’s manufacturing and fill-finish network plus government-activated secondary manufacturers. Supply depends on contract awards, batch release capacity, and regulatory quality controls rather than open-market wholesalers.

Who are the TPOXX (tecovirimat) drug product suppliers and manufacturers?

Primary sources of supply

• SIGA Technologies is the developer and the key market-structure origin point for TPOXX supply planning.
• Government-linked manufacturing and contract manufacturers supply finished drug product under public-sector demand surges. These suppliers are typically activated via U.S. government procurement and contract frameworks tied to strategic stockpiles and emergency readiness.

How “supplier” breaks down in practice

1. Marketing authorization holder / drug owner: SIGA Technologies (brand owner for TPOXX in the U.S.).
2. Drug product manufacturing: performed by SIGA’s internal capabilities and/or contracted drug product manufacturers for surge capacity.
3. Fill-finish and packaging: performed under controlled quality systems by CMO fill-finish partners.
4. Active pharmaceutical ingredient (API) supply: sourced through qualified API manufacturers; API supply is the most common bottleneck during surge manufacturing.
5. Government distribution: managed through federal procurement and distribution channels for stockpile delivery, not standard retail supply.

Which companies provide fill-finish for TPOXX?

Fill-finish suppliers are chosen under qualification status (GMP history, comparability, and analytical method transfer) and are usually disclosed in regulatory manufacturing sections (e.g., labels, submissions, or inspection records) rather than in consumer-facing channels. For TPOXX, fill-finish and packaging capacity is a recurring constraint during public-health demand spikes.

Which companies provide the tecovirimat API?

API suppliers for tecovirimat are selected based on ability to deliver consistent impurity profiles, stability, and validated synthesis steps at scale. API qualification is a key gating factor for expanding supplier networks.

What patents protect tecovirimat (TPOXX) and how does that affect suppliers?

Supplier impact is mostly indirect

• Patent coverage shapes manufacturing access through process, formulation, and use claims, and it shapes whether third parties can produce licensed product without infringing.
• For TPOXX, the supplier universe is constrained by the need to maintain controlled quality and avoid unauthorized manufacture routes that could conflict with IP ownership or licensing structures.

How strong is the patent estate for tecovirimat that could block new suppliers?

The practical effect for sourcing is:

• New manufacturers need a legally cleared route (license or non-infringing process).
• Regulatory filing and batch release require validated methods and comparability packages, which increases time-to-qualification.
• Contracting often favors incumbent or government-approved suppliers.

What is the FDA regulatory status of TPOXX and where do suppliers show up in FDA records?

Regulatory signal for supply

• FDA labels and product manufacturing sections are the primary public artifacts where drug product and manufacturing site responsibility appear.
• During supply expansions, the “site list” can change through supplement filings, which is the operational record that indicates supplier additions.

What should procurement teams check in FDA labeling to confirm the supplier?

• Labeled manufacturing location(s) for drug product.
• Labeled packaged by / distributed by firms for commercial vs emergency supply contexts.
• Any disclosed establishment identifiers that map to GMP inspection records.

When does TPOXX lose exclusivity and can that change the supplier landscape?

Exclusivity and entry are schedule-driven

• If IP or regulatory exclusivity expires, supplier count can increase via:
  • New contract manufacturing under non-infringing production routes.
  • License-driven expansion by third parties with validated chemistry and regulatory readiness.
• In TPOXX’s case, public-sector contracting and strategic stockpile governance can keep the supplier base narrower even after exclusivity milestones, because procurement rules often prefer prequalified capacity.

What generic entry risks exist for tecovirimat affecting suppliers?

• Generic or alternative producers must clear both:
  • Regulatory pathway requirements (bioequivalence or alternative demonstrating sameness where applicable).
  • IP barriers (non-infringement, invalidity, or licensing).

How many TPOXX suppliers exist across API, drug product, and fill-finish?

Answer in operational terms

• The supplier footprint is typically smaller than common chronic-care products because TPOXX is:
  • Indicated for an emergency antiviral use-case,
  • Dependent on surge manufacturing capacity,
  • Subject to tighter government procurement control,
  • Often produced under controlled licensing and government contracting.

A “single-API + one or two drug product/finish sites” model is a common configuration for surge antivirals, but the exact number of qualified suppliers is recorded in FDA submissions and labeling site sections and is reflected contract-by-contract during procurement.

Which government programs influence TPOXX supplier selection?

Supply is driven by stockpile readiness

• U.S. federal purchasing for preparedness and emergency use drives supplier activation and release schedules.
• Contracts prioritize:
  • Manufacturing slot availability,
  • GMP track record,
  • Ability to meet release specifications on compressed timelines,
  • Production scalability and supply continuity.

How does TPOXX supply compare with other antiviral surge products in supplier structure?

Pattern

• Unlike routine commercial therapeutics, TPOXX supply tends to resemble:
  • Stockpile-based procurement structures,
  • Multi-site contingency manufacturing,
  • License-constrained sourcing for chemistry and packaging.

Key Takeaways

• TPOXX (tecovirimat) suppliers are driven by a constrained, government-activated manufacturing ecosystem rather than broad retail wholesaling.
• SIGA Technologies is the central origin point for commercial control and supply planning.
• API, drug product manufacturing, and fill-finish are each a bottleneck tier, with qualification and IP clearance shaping who can be added.
• Supplier additions typically appear through FDA labeling/manufacturing site updates and contract-driven production expansions.

FAQs

1. How can procurement teams verify the TPOXX manufacturer for a given lot?
   Check the FDA label and carton labeling for manufacturing site identifiers and lot release/distribution documentation tied to that lot.

2. Do TPOXX suppliers differ between commercial supply and emergency stockpile supply?
   Yes. Emergency supply often uses prequalified surge-capacity sites under government contracts.

3. What are the main supply bottlenecks for tecovirimat?
   API availability, drug product batch capacity, and fill-finish slot availability under GMP controls.

4. Can a new CMO make tecovirimat without infringing tecovirimat patents?
   Entry depends on non-infringing manufacturing routes and legal clearance, not only technical capability.

5. Where is TPOXX supplier information most reliably documented?
   FDA label manufacturing sections, site listings in regulatory submissions, and lot-specific carton labeling.

---

References

1. FDA. TPOXX (tecovirimat) drug label and prescribing information. U.S. Food and Drug Administration.
2. SIGA Technologies. TPOXX (tecovirimat) product information and corporate disclosures.
3. FDA. Drug product manufacturing and establishment information in FDA labeling and submissions for tecovirimat.

Note: No additional supplier names can be provided without specific FDA-label or regulatory-site evidence for tecovirimat manufacturing, because supplier attribution must be tied to publicly listed manufacturing/packaging establishments or verified corporate disclosures.